AmpliPhi Biosciences is focused on developing novel bacteriophage-based therapeutics.
Business Model:
Revenue: $0
Employees: 11-50
Address:
City: Richmond
State: Virginia
Zip:
Country: United States
AmpliPhi Biosciences is a biopharmaceutical company focused on the development of an internally generated pipeline of naturally occurring viruses called bacteriophage (phage) for the treatment of bacterial infection. Phage-based therapy provides a unique and proven approach to treating a wide variety of bacterial infections and in particular, drug-resistant strains of bacteria that are commonly found in the hospital setting. We have built a drug development and manufacturing platform designed to allow rapid development and production of multiple phage-based therapies. Our plan and success relies on our ability to identify and develop selected phage to eradicate targeted bacterial infections across a wide range of bacterial disease. Initially our phage discovery and development platform will focus efforts in acute and chronic lung, sinus and gastrointestinal (GI) infections. AmpliPhi maintains operations in Richmond, Virginia in the United States, in Colworth Science Park, near London in the United Kingdom, and outside Sydney, NSW, Australia.
Contact Phone:
Contact Email:
Listed Exchange:
NYSE
IPO Date:
5/12/2006
Ticker Symbol:
APHB
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 1/2004 | Venture Round | 1 | - |
Venrock Venrock |
3/2015 | Post-IPO Equity | $13M | 12/2013 | Post-IPO Equity | 1 | $18M |
ROTH Capital Partners ROTH Capital Partners |
7/2013 | Post-IPO Equity | $0 |
RA Capital Management BioScience Managers Limited Third Security RA Capital Management BioScience Managers Limited Third Security |
2/2013 | Post-IPO Debt | $500k | 7/2013 | Post-IPO Equity | 3 | $12.5M |
RA Capital Management BioScience Managers Limited Third Security RA Capital Management BioScience Managers Limited Third Security |
1/2004 | Venture Round | 1 | - |
Venrock Venrock |
---|
Announced Date | Name | Price |
---|---|---|
1/2019 | C3J Therapeutics | |
1/2016 | Novolytics | |
1/2011 | Biocontrol |
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|